Smoking Cessation: The Most Powerful 'Respiratory Drug' of All
Stopping smoking does more for a person's lungs, heart and lifespan than any inhaler ever could — it's the single most effective intervention in respiratory medicine. And because nicotine is powerfully addictive, we have real pharmacology to help: three main approaches that make quitting genuinely achievable.
Throughout the COPD articles, one intervention kept coming up as the most important of all: stopping smoking. It's worth stating plainly — no drug in this entire section, no inhaler or steroid or biologic, comes close to the benefit of quitting cigarettes. Stopping smoking slows the relentless decline of COPD (it's the only thing that does), and it dramatically cuts the risk of lung cancer, heart attack and stroke. But cigarettes are hard to give up because nicotine is a genuinely addictive drug: it acts on nicotinic receptors in the brain's reward system (a callback to the autonomic chapter, where you first met nicotinic receptors), creating dependence and unpleasant withdrawal when someone tries to stop. So we treat that addiction with pharmacology, and there are three main tools.
The three approaches
Replace the nicotine, or block its effect in the brain. The first and simplest approach is nicotine replacement therapy (NRT): giving nicotine itself in a cleaner form — patches, gum, lozenges, sprays — without the tar, carbon monoxide and carcinogens of tobacco smoke. This eases the cravings and withdrawal, letting the person break the behavioural habit first and taper the nicotine later. Patches give a steady background level, while faster forms (gum, spray) handle sudden cravings — often the two are combined. The second approach is varenicline, a clever drug that acts as a partial agonist at the nicotinic receptor. This dual action is elegant: it partially stimulates the receptor (easing withdrawal, so the person doesn't feel so deprived) while also blocking nicotine from binding (so if they do smoke, it's far less rewarding). It's one of the most effective aids, though it was scrutinised for possible mood effects and should be used with awareness of the person's mental health. The third is bupropion, an antidepressant that also reduces cravings and withdrawal through effects on brain chemistry; it's an alternative, but carries a caution — it can lower the seizure threshold, so it's avoided in people at risk of seizures. Behind all three sits the same truth: medication roughly doubles the chance of quitting successfully, but it works best combined with behavioural support and determination.
Why it belongs in respiratory medicine
It might seem odd to end the acute-care section with an addiction treatment, but smoking cessation is arguably the most important prescription in the whole respiratory chapter. Consider the arithmetic: for a patient with COPD, an inhaler eases symptoms but doesn't halt the disease; stopping smoking is the ONLY intervention that actually slows the loss of lung function over the years to come. It's cheap, it works, and its benefits ripple far beyond the lungs — heart, blood vessels, and cancer risk all improve. That's why good respiratory care always includes asking about smoking and offering help to quit, at every opportunity. The pharmacology here is genuinely useful, roughly doubling success rates, but its real message is one of priorities: before reaching for another inhaler in a smoker, the most powerful thing you can do for their lungs is help them stop the smoke. In a section full of clever drugs, the humble act of quitting outperforms them all.
- Stopping smoking is the single most effective intervention in respiratory medicine — the only thing that slows COPD decline.
- Nicotine is addictive (acts on nicotinic receptors); three drug approaches help quitting.
- NRT (patches/gum/lozenge/spray): cleaner nicotine to ease cravings; combine steady + fast forms.
- Varenicline = partial nicotinic agonist (eases withdrawal + blocks nicotine's reward); very effective.
- Bupropion (antidepressant) is an alternative but lowers the seizure threshold.
Varenicline is a beautiful illustration of the partial agonist idea. A full agonist switches a receptor fully on; an antagonist blocks it completely. A partial agonist does something cleverer — it turns the receptor partly on, which means it can act as EITHER a mild stimulator or a blocker depending on what else is around. At the nicotinic receptor, this is perfect for quitting: on its own, varenicline gently stimulates the receptor just enough to take the edge off withdrawal, so the person doesn't feel desperate. But because it's occupying the receptor, it simultaneously blocks nicotine from binding — so if they give in and smoke a cigarette, the usual hit of reward is largely gone, and the habit loses its payoff. One drug that soothes the craving and defuses the relapse, all from the single trick of being a partial agonist.
- Reaching for another inhaler in a smoker before addressing the smoking itself.
- Using bupropion in someone with a seizure risk — it lowers the seizure threshold.
- Relying on medication alone — success is highest combined with behavioural support.
- Using only a nicotine patch for sudden cravings — add a fast form (gum/spray).
Which single intervention most effectively slows the decline of COPD?
- Stopping smoking is the most effective respiratory intervention — the only thing that slows COPD decline.
- NRT gives cleaner nicotine to ease cravings; combine steady (patch) + fast (gum/spray) forms.
- Varenicline (partial nicotinic agonist) eases withdrawal and blocks nicotine's reward — very effective.
- Bupropion is an alternative but lowers the seizure threshold; combine drugs with behavioural support.
- Katzung BG. Basic & Clinical Pharmacology — Drugs of Abuse (nicotine) & smoking cessation.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Smoking cessation pharmacotherapy.
- NICE / USPSTF — Stop smoking interventions and services.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Smoking cessation agents.
